Skip to content
10-Q

Quarterly Report

Yew Bio-Pharm Group, Inc.

0001213900-19-009396

← back to feed
Filed
May 22, 2019 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2019 · May 22, 2019 51.7M sh
Short Term Debt Q1 2019 · Mar 31, 2019 $5.52M
Short Term Debt Q1 2019 · Dec 31, 2018 $5.76M
Current Liabilities Q1 2019 · Mar 31, 2019 $9.13M
Current Liabilities Q1 2019 · Dec 31, 2018 $7.06M
Total Liabilities Q1 2019 · Mar 31, 2019 $10.97M
Total Liabilities Q1 2019 · Dec 31, 2018 $8.61M
Current Assets Q1 2019 · Mar 31, 2019 $15.89M
Current Assets Q1 2019 · Dec 31, 2018 $12.39M
Total Assets Q1 2019 · Mar 31, 2019 $53.46M
Total Assets Q1 2019 · Dec 31, 2018 $49.69M
Shares Diluted Q1 2019 · Mar 31, 2018 60.08M sh
Operating Cash Flow Q1 2019 · Mar 31, 2018 $10.92M
Cash And Equivalents Q1 2019 · Mar 31, 2018 $23.05K
Cash And Equivalents Q1 2019 · Dec 31, 2017 $859.83K
Stockholders Equity Q1 2019 · Mar 31, 2018 $46.88M
Stockholders Equity Q1 2019 · Dec 31, 2017 $45.17M
Eps Diluted Q1 2019 · Mar 31, 2018 $0.00
Eps Basic Q1 2019 · Mar 31, 2018 $0.00
Sga Expense Q1 2019 · Mar 31, 2018 $257.38K
Net Income Q1 2019 · Mar 31, 2018 $149.01K
Operating Income Q1 2019 · Mar 31, 2018 $219.42K
Gross Profit Q1 2019 · Mar 31, 2018 $479.3K
Cost Of Revenue Q1 2019 · Mar 31, 2018 $2.55M